UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet Distance in 5 Minutes

UltraViolet Devices Inc. (UVDI) has announced that its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10, inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters).

oneSOURCE Creates Free Resource Page with Up-to-Date COVID-19 Vaccine Information

Today, oneSOURCE, an RLDatix company and leading healthcare management solution, announced a new COVID-19 vaccine resource page to assist healthcare professionals during the initial administration phases of the vaccine.

STERIS to Acquire Cantel Medical

STERIS plc and Cantel Medical Corp. announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers.

NEC Releases ‘WISE VISION Endoscopy’ in Europe and Japan

NEC Corporation has announced the development of “WISE VISION Endoscopy,” an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan and is expected to soon be available in Europe.

Diversey Announces Efficacy Testing Against SARS-CoV-2

Diversey, Inc., a global leader in healthcare and infection prevention products and solutions, today announced it will test several of its disinfectant products for efficacy against SARS-CoV-2, which causes COVID-19.  These results will be submitted to the EPA for approval.

“With a mission to protect and care for people every day, infection prevention is a major focus for Diversey,” said Mark Copeland, CMO for Diversey, Inc.  “Up until now, healthcare providers and others have been looking at the EPA’s Emerging Viral Pathogens Program for guidance, and more recently for claims against human coronavirus, on what products may work as disinfectants based on knowledge of similar pathogens. The Emerging Viral Pathogens Program is intended to bridge the gap between when outbreaks occur and novel viruses are available to test for specific product efficacy.”

Diversey has partnered with Microbac Laboratories, Inc. to test several of its products for effectiveness against SARS-CoV-2.  Microbac is a leading testing laboratory that offers antiviral and antimicrobial efficacy testing for various disinfectants, sanitizers, antiseptics, and devices, against SARS, MERS, and other microorganisms. Microbac is one of the only testing laboratories in the world certified by the CDC to test the effectiveness of products against SARS-CoV-2 and viruses like it.

“Protecting the public against SARS-CoV-2 is an all-hands-on-deck issue,” said Trevor Boyce, Microbac’s Chairman and CEO. “We are eager to apply our scientific knowledge and experience to our work with a global leader like Diversey, to develop new tools in the fight against this pandemic.”

“Creating a safer environment for all people, including patients, providers, and the public, is critical in this time, and Diversey is committed to continue to provide products and practices to optimize outcomes,” added Copeland.

This test data will not replace the EPA List N and guidelines for disinfectants for use against SARS-CoV-2 at this time.  All products on this list meet EPA’s criteria for use against SARS-CoV-2, the virus that causes COVID-19.  The testing will provide added assurance for specific efficacy against this virus.  Until there is further EPA guidance, disinfectants found on the EPA’s List N should continue to be used according to their label instructions.

The following Diversey products can be found on List N:



Submit a Comment

Your email address will not be published. Required fields are marked *